Modakafusp alfa binds CD38 on target cells and delivers attenuated IFN-α that engages IFNAR1/2 on those same cells, activating JAK–STAT type I IFN signaling to induce antiproliferative/apoptotic effects. IFNAR1 is the executing receptor for the payload, not the antibody’s binding target.